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Abstract
Background: The polymorphic nature of many malaria vaccine candidates presents major challenges to achieving
highly efficacious vaccines. Presently, there is very little knowledge on the prevalence and patterns of functional
immune responses to polymorphic vaccine candidates in populations to guide vaccine design. A leading
polymorphic vaccine candidate against blood-stage Plasmodium falciparum is apical membrane antigen 1
(AMA1), which is essential for erythrocyte invasion. The importance of AMA1 as a target of acquired human
inhibitory antibodies, their allele specificity and prevalence in populations is unknown, but crucial for vaccine
design.
Methods: P. falciparum lines expressing different AMA1 alleles were genetically engineered and used to
quantify functional antibodies from two malaria-exposed populations of adults and children. The acquisition
of AMA1 antibodies was also detected using enzyme-linked immunosorbent assay (ELISA) and competition
ELISA (using different AMA1 alleles) from the same populations.
Results: We found that AMA1 was a major target of naturally acquired invasion-inhibitory antibodies that
were highly prevalent in malaria-endemic populations and showed a high degree of allele specificity.
Significantly, the prevalence of inhibitory antibodies to different alleles varied substantially within populations
and between geographic locations. Inhibitory antibodies to three specific alleles were highly prevalent (FVO
and W2mef in Papua New Guinea; FVO and XIE in Kenya), identifying them for potential vaccine inclusion.
Measurement of antibodies by standard or competition ELISA was not strongly predictive of allele-specific
inhibitory antibodies. The patterns of allele-specific functional antibody responses detected with our novel
assays may indicate that acquired immunity is elicited towards serotypes that are prevalent in each
geographic location.
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Conclusions: These findings provide new insights into the nature and acquisition of functional immunity to
a polymorphic vaccine candidate and strategies to quantify functional immunity in populations to guide
rational vaccine design.
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Background
The development of effective vaccines is a major global
goal towards achieving malaria control and elimination.
However, a major challenge in the development of highly
efficacious vaccines is antigen polymorphism, which is
an important issue for many leading vaccine candidates.
This includes the RTS,S vaccine, which recently com-
pleted phase III trials, and vaccines based on apical
membrane antigen 1 (AMA1) and merozoite surface
protein 2 (MSP2); for all these candidates, vaccine effi-
cacy against malaria or Plasmodium falciparum infection
was higher for episodes caused by vaccine-like strains
compared to vaccine-dissimilar strains [1–3]. Currently,
knowledge on the distribution and prevalence in popula-
tions of functional immune responses to different alleles
or strains for polymorphic vaccine candidates is very
limited, but would be highly valuable for guiding vaccine
design. A further constraint to vaccine development is a
paucity of data on the targets of functional immune re-
sponses that may mediate protective immunity. Anti-
bodies form an important component of acquired
human immunity [4–6]. Merozoite antigens are import-
ant targets of antibodies that inhibit erythrocyte inva-
sion, limit parasite replication and control disease
associated with blood stage replication [5, 7]. However,
the major targets of acquired invasion-inhibitory anti-
bodies are unclear.
The merozoite protein apical membrane antigen 1
(AMA1) is a leading polymorphic vaccine candidate that
plays an essential role in host cell invasion and is a prom-
inent target of naturally acquired antibodies [7–9]. AMA1
binds the rhoptry neck protein, RON2, a key interaction
that is required for formation of the tight junction during
invasion [10, 11], and antibodies to AMA1 inhibit inva-
sion in vitro [12–18]. In malaria-exposed individuals, anti-
bodies to AMA1 are highly prevalent, increasing with age
and exposure [19–22], and some studies have found anti-
bodies to AMA1, measured by standard enzyme-linked
immunosorbent assay (ELISA), are associated with protec-
tion from malaria in longitudinal studies [7, 8, 20, 23–27].
Affinity-purified human antibodies to AMA1 can inhibit
invasion [12], and some people acquire antibodies to in-
hibitory epitopes of AMA1 [28]. However, the significance
of AMA1 as a target of acquired invasion-inhibitory anti-
bodies and the strain specificity and prevalence of these
antibodies remain unknown [29].
AMA1 is highly polymorphic with more than 200 hap-
lotypes, and reflects the challenges faced in vaccine
development of overcoming antigenic diversity to enable
highly efficacious vaccines [12–15, 30–32]. Humans gen-
erate both allele-specific and cross-reactive antibodies to
AMA1 [20, 21, 32], but how these antibodies are
acquired and their relative contribution to protection re-
main uncertain, particularly for functional antibodies. A
phase II trial in Malian children of an AMA1 vaccine
containing a single allele demonstrated significant
strain-specific efficacy, reducing the risk of malaria
caused by vaccine-like strains (defined by genotype) [2].
These results provide an important proof of concept for
AMA1-based vaccines, but highlight the need to under-
stand AMA1 antigenic diversity and address this diver-
sity in vaccine design. Although there are more than 200
AMA1 haplotypes, antigenic diversity appears more lim-
ited than suggested by sequence diversity [31, 32]. Popu-
lation genetics suggest that the distribution of AMA1
haplotypes, or major haplotype groupings, is similar
across different geographic regions and that there is a
similar proportion of major haplotype clusters within a
population [33, 34]. However, data on the acquisition of
functional antibodies in populations is absent due to a lack
of tools to measure these antibodies. Understanding these
issues is crucial for vaccine design with respect to select-
ing alleles for inclusion in future vaccines and determining
whether vaccine formulations may need to differ between
regions. Similar needs exist for many other vaccine candi-
dates for which antigenic diversity is a key issue [1, 35].
To date, there has been no way of quantifying natur-
ally acquired AMA1-specific invasion-inhibitory anti-
bodies in human populations or quantifying the
prevalence of allele-specific functional antibodies. More-
over, the prevalence of allele-specific functional anti-
bodies has not been reported for any malaria antigen to
date, because of a lack of tools and approaches. In this
study we used AMA1 as a model to investigate the pat-
terns, prevalence and nature of acquired functional immun-
ity to a polymorphic vaccine candidate. We developed a
novel approach using genetically engineered P. falciparum
lines expressing one of six antigenically distinct AMA1
alleles that broadly represent global antigenic diversity
[15, 31]. The development of these novel tools enabled
us to evaluate the importance of AMA1 as a target of
human invasion-inhibitory antibodies, determine the
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extent to which inhibitory antibodies are cross-reactive
and allele-specific and determine whether the preva-
lence of inhibitory antibodies varies for different allelic
serotypes. This knowledge will be highly valuable in
selecting alleles for potential vaccine inclusion and
advancing our understanding of strain-specific protection,
which is a feature of immunity to malaria and relevant to
many malaria vaccine candidates.
Methods
Aim
The aim of this study was to measure and compare the
prevalence and allele specificity of naturally acquired
growth inhibitory antibodies to a polymorphic malaria
antigen (AMA1) across two geographically distinct loca-
tions (Kenya and Papua New Guinea) to inform the design
of future vaccines incorporating polymorphic antigens.
Design
P. falciparum lines were genetically engineered to ex-
press one of six antigenically distinct alleles of AMA1
and were used in in vitro growth inhibition assays
(GIAs) to measure the presence of AMA allele-specific
functional antibodies in samples from children and
adults in Papua New Guinea and adults living in
Kenya. Antibodies to AMA1 were also quantified by
standard ELISA and competition ELISA.
Study population and setting
Blood was collected (in 2004) from adults and children
participating in a cross-sectional study in Madang Prov-
ince, Papua New Guinea (PNG), a region that experi-
ences year-round malaria transmission with seasonal
variation [32, 36]. Sera were collected from 50 adults
(median age 28 years (interquartile range, IQR 24.8–35))
and 49 children (median age 7 years (IQR 6–9)), with
53 % male and 48.2 % being positive for parasitemia
(18 % P. falciparum; 26 % P. vivax; 4 % P. malariae; 5 %
mixed infections). Serum samples were also collected
from adult residents (n = 54) of Nyanza Province, Kenya,
an area of high malaria transmission [37]. Sera from non-
immune Melbourne donors (provided by the Australian
Red Cross Blood Service) were used as negative controls.
Ethical approval was obtained from the Medical Research
Advisory Committee, PNG, Kenya Medical Research
Institute, Walter and Eliza Hall Institute and Alfred
Health Human Research Ethics Committees, Australia.
Antibodies, immunoblots and ELISA
Rabbit antisera against recombinant, refolded AMA1
ectodomains were generated and purified as described
[12, 31]. Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblot analysis of
parasite proteins was performed as previously described
[31]. Standard ELISAs to measure AMA1 antibodies in
plasma and competition ELISAs with different AMA1
alleles were also performed as described [8, 32]. See
Additional file 1 for more details.
Parasite lines, culture and invasion inhibition assays
Wild-type W2Mef P. falciparum and transgenic W2Mef
P. falciparum genetically engineered to express one of
six different AMA1 alleles were cultured in vitro [31].
Transgenic lines expressing W2Mef, 3D7 and FVO
AMA1 alleles were generated in a previous study [31],
while lines expressing HB3, XIE and Pf2006 AMA1
alleles were generated in this study using previously de-
scribed techniques [31]. Flow cytometry-based invasion
inhibition assays were performed as described in detail
elsewhere [6, 31, 38, 39]. In brief, synchronised P. falcip-
arum (pigmented trophozoite stage) from culture was
adjusted to 0.1 % parasitemia and 2 % haematocrit for
assay set-up. Human serum samples were tested for
growth inhibition at 1/10 dilution in duplicate or tripli-
cate wells in a 96-well format. Parasites were allowed to
develop through two cycles of erythrocyte invasion for
72 hours at 37 °C. Parasitemia was evaluated by flow
cytometry (see Additional file 1 for further details). All
PNG samples were tested in duplicate in at least two in-
dependent assays; the means of all results (duplicate
wells and assays) were used in analysis. Subsequently, a
subset of 66 samples was tested in duplicate in a repeat
assay against all six parasite lines in parallel to further
validate and confirm the findings obtained. After estab-
lishing the approach and reproducibility with the PNG
samples, all Kenyan samples were tested together against
all six AMA1 transgenic lines in duplicate in a single
assay, and the mean of the results for each sample was
used for analysis. Samples from malaria-naïve Australian
residents were included as non-immune controls in all
assays. AMA1-specific invasion inhibition was consid-
ered to be present in a sample if the sample inhibited
one of the genetically engineered P. falciparum lines
compared with other lines tested at the same time in
parallel by at least 10 % or higher greater (defined as the
absolute difference of 10 % or higher, not a relative
difference of 10 %).This cut-off was selected on the
following basis. (1) Variation in the assay was estimated
as +/-2 standard deviations around the mean of the
Melbourne control sera used in assays; 2 standard devia-
tions was used to define our ‘variation threshold’, and
this value was always less than 10 % across assays, as we
have found in previous studies [39]. Assay variance was
similar when using samples from our study populations
(examples are shown in Fig. 3 and will be discussed
below in the Results section). (2) It was considered that
an absolute difference of 10 % was currently regarded as
an acceptable difference when reporting results from
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inhibition assays. To assess assay variation, we calculated
the coefficient of variation (which represents standard
deviation relative to the mean; CV). The CV values for
the sample sets tested were as follows: 2.2–4.6 % for in-
dividual malaria non-exposed control samples; 3.2–4 %
for PNG samples and 3.6–6.6 % for Kenyan samples (the
range of CV values shown represents values calculated
across different assays and using different AMA1 trans-
genic lines). Detailed evaluations of the reproducibility
and precision of these assays and their application in
measuring antigen-specific inhibitory antibodies have
been published elsewhere [6, 38–41].
Statistical analysis
Analyses were performed using GraphPad Prism 5. Inva-
sion inhibition of different P. falciparum lines was com-
pared by paired t test, or Wilcoxon’s matched-pairs
signed-rank sum test for non-parametric data. Preva-
lence of AMA1 antibodies or prevalence of specific inva-
sion inhibition was compared using the chi-squared test
or Fisher’s exact test. The Mann-Whitney test was used
to compare antibody levels. Spearman’s correlation coef-
ficient was used to assess associations between anti-
bodies to different AMA1 alleles measured by ELISA,
and between invasion inhibition and AMA1 antibodies.
Results
Construction and phenotyping of genetically engineered
P. falciparum lines
We generated P. falciparum isolates from a common
parental line (W2Mef) which were genetically engi-
neered to express one of six different AMA1 alleles that
broadly represent the antigenic diversity of AMA1, in-
cluding alleles from our study population [31, 32]. We
have previously described the generation of W2Mef
parasite lines that express W2Mef, 3D7 or FVO AMA1
alleles (W2-W2, W2-3D7 and W2-FVO, respectively
[31]). Here, we expanded our repertoire of genetically
engineered lines to include W2Mef parasites that ex-
press HB3, XIE or Pf2006 AMA1 alleles (W2-HB3, W2-
XIE and W2-2006, respectively). We constructed plas-
mids containing codon-optimised HB3, XIE and Pf2006
AMA1 alleles (Fig. 1a). These plasmids were transfected
into W2Mef parental parasites and successfully inte-
grated into the wild-type (WT) AMA1 locus following
drug selection (Fig. 1b). In invasion inhibition assays
using W2Mef AMA1 antibodies (generated in rabbits),
no significant difference in growth inhibition was de-
tected between W2Mef parental and the genetically
engineered W2-W2 parasites used as a transgenic con-
trol line (Fig. 1c), confirming that both strains express
equivalent amounts of W2Mef AMA1. All other genetic-
ally engineered strains were significantly less inhibited
by W2Mef AMA1 anti-serum than the W2Mef parental
strain, confirming the loss of endogenous W2Mef
AMA1 expression (paired t test P < 0.05, Fig. 1c). Whilst
W2-3D7 and W2-FVO parasites effectively escaped
W2Mef AMA1 antibody inhibition, W2-HB3, W2-XIE
and W2-2006 genetically engineered parasites were still
inhibited to some degree, consistent with known cross-
strain AMA1 antibody inhibition [16, 31].
The correct expression of AMA1 alleles in genetic-
ally engineered P. facliparum lines was also confirmed
by Western blot (Additional file 1: Figure S1) and in-
hibition assays with WT parasite strains (Fig. 1d). P.
falciparum expressing W2mef, 3D7 and FVO alleles
have previously been shown to express the correct
allele of AMA1 [31], and this was also shown for
W2-HB3 parasites (Additional file 1: Figure S1A). As
we did not have antibodies raised against the XIE or
Pf2006 AMA1 alleles, expression of these alleles in
W2-XIE and W2-2006 parasites was confirmed by
probing Western blots with HB3 AMA1 antibodies,
which cross-reacted with these alleles sufficiently
strongly for detection in Western blots, but not with
W2Mef AMA1 (Additional file 1: Figure S1B, C).
Parental and genetically engineered parasite lines ex-
pressing the same AMA1 alleles showed equivalent
levels of invasion inhibition with allele-specific anti-
bodies (Fig. 1d), and 3D7-WT and W2-3D7 lines were
equally inhibited by the AMA1-binding protein R1
(data not shown), further demonstrating that the level
of AMA1 expressed in the parental and transfected
lines was similar.
Human AMA1 antibodies measured by ELISA
We first measured antibodies to recombinant AMA1 in
the PNG study population by standard ELISA. The
prevalence of AMA1 antibodies was high (>90 %) and
similar for each of the six AMA1 alleles that were
expressed by the genetically engineered P. falciparum
lines (chi-square P = 0.07). See Fig. 2; (relative antibody
levels are shown in Additional file 1: Figure S2). Anti-
body responses were strongly correlated between alleles
(Spearman’s ρ = 0.74–0.97, P < 0.0001).
Allele-specific AMA1 invasion-inhibitory antibodies
Differential invasion inhibition of AMA1 genetically
engineered P. falciparum lines by serum antibodies from
malaria-exposed individuals provided evidence that
AMA1 is a target of naturally acquired invasion-
inhibitory antibodies (Fig. 3a and b). Invasion inhibition
was considered specific if there was at least 10 % or
greater inhibition (absolute difference) of one genetic-
ally engineered P. falciparum line compared with
either of two other lines tested at the same time in
parallel (Fig. 4a). It was striking to see a substantially
higher prevalence of inhibitory antibodies for FVO
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and W2mef compared to other alleles (Fisher’s exact
test, P < 0.0001 (Fig. 4a)), despite there being a similar
prevalence of total immunoglobulin G (IgG) to each
allele when measured by standard ELISA; levels of
antibodies determined by ELISA were not clearly pre-
dictive of the pattern of inhibitory antibodies (Add-
itional file 1: Figure S2). The prevalence of specific
invasion inhibition for each AMA1 allele was not
markedly different between adults and children (P =
0.09) (Additional file 1: Figure S3A). Pair-wise com-
parisons between different AMA1 lines for inhibition
by serum antibodies further demonstrated that the
prevalence of invasion-inhibitory samples was sub-
stantially higher for FVO and W2mef than for com-
parison alleles (Fig. 4b). Furthermore, the levels of
inhibitory antibodies were higher for FVO and
W2mef than for the comparison lines. For example,
inhibition of the FVO expressing line was significantly
greater than 3D7 (P < 0.0001; Wilcoxon’s matched-
pairs signed-rank sum test), and inhibition of W2mef
was significantly greater than XIE or Pf2006 (P < 0.01
and P < 0.05, respectively). There was no significant
difference in prevalence between children and adults
for any comparison (Fisher’s exact test, P > 0.12)
(Additional file 1: Figure S3B). These findings clearly
indicate that the prevalence and levels of inhibitory
antibodies to different AMA1 alleles vary significantly
within a population, which was not clearly evident
from standard ELISA approaches, and has significant
implications for vaccine design.
Fig. 1 Generation and phenotypic analysis of P. falciparum lines genetically engineered to express different AMA1 alleles. a Plasmid design and
integration: HB3, XIE and Pf2006 codon-optimised AMA1 alleles were transfected into W2Mef parental parasites. The single crossover event for
allelic replacement of the W2Mef wild-type (WT) AMA1 with the codon-optimised AMA1 alleles (AMA1co) is illustrated. b Southern blots: genomic DNA
from parental W2Mef (W2Mef WT) and genetically engineered parasite lines (W2-W2, W2-3D7, W2-FVO, W2-HB3, W2-XIE and W2-2006) were digested
with restriction enzymes as indicated. Expected sizes for WT, non-integrated plasmid and for integrated codon-optimised AMA1 alleles are shown in
kilobases (kb). c Differential invasion inhibition of W2Mef and genetically engineered parasite lines in the presence of W2Mef AMA1 rabbit anti-serum
(1:10 dilution) in a two-cycle growth inhibition assay (GIA). Columns represent the mean percentage growth inhibition (relative to a non-inhibitory
control) achieved in two separate assays tested in triplicate wells. Antibody inhibition was significantly lower for W2-3D7, W2-HB3, W2-FVO, W2-2006 and
W2-XIE than for W2mef parental or W2-W2 (P < 0.05 by paired t test). d Antibody-mediated invasion inhibition of wild-type or genetically engineered
P. falciparum expressing the same AMA1 allele was compared in GIAs. Total inhibition is expressed as the mean of two separate assays performed in
triplicate. n = 6 for each group listed. Error bars indicate + standard error of the mean (SEM). Statistical analysis was by paired t test
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Specificity and relatedness of invasion-inhibitory
responses
Analysis of the specificity or cross-reactivity of inhibitory
antibodies revealed that most serum samples were not
broadly cross-inhibitory with few samples inhibiting
more than two different AMA1 lines (Fig. 4c, Additional
file 1: Table S1). Children and adults showed some dif-
ferences in the profile of allele-specific inhibitory activity
(Fig. 4d), with a higher proportion of children showing
no specific inhibition of any genetically engineered P.
falciparum line (Fisher’s exact test P = 0.053), and a
greater proportion of adults had specific inhibitory activ-
ity against one genetically engineered P. falciparum line
(P = 0.024).
The pattern of overlap suggested individuals had pre-
dominantly acquired mixtures of allele-specific invasion-
inhibitory antibodies of multiple specificities, rather than
truly cross-inhibitory antibodies. Overlap in inhibitory
activity was related to the prevalence of specific inhibi-
tory antibodies targeting each AMA1 allele. A sample
with inhibitory activity specific for any AMA1 allele was
most likely to show concurrent inhibitory activity against
FVO and/or W2mef (Fig. 5a, Additional file 1: Table S1),
because the prevalence of inhibitory antibodies to these
AMA1 alleles was highest. Whilst a proportion of sam-
ples inhibited both FVO and W2mef lines (49 % of FVO
inhibitors also inhibited W2mef and 35 % of W2mef in-
hibitors also inhibited FVO) (Fig. 5b, Additional file 1:
Table S1), a considerable number of samples only inhib-
ited one line or the other, consistent with these anti-
bodies being allele-specific rather than cross-inhibitory.
When samples that showed overlap in invasion-
inhibitory activity were compared with those that inhib-
ited only a single genetically engineered P. falciparum
line (e.g. FVO and W2mef versus FVO only), no differ-
ence was observed in antibody level by ELISA (P > 0.347,
Mann-Whitney U test) or absolute invasion inhibition
(P > 0.7011) (Additional file 1: Figure S4). This suggests
that overlap in invasion-inhibitory activity is not related
to antibody magnitude.
Invasion inhibition versus AMA1 antibodies measured by
standard ELISA
Our analysis considered the relationship between AMA1
antibodies by ELISA and AMA1-specific inhibitory anti-
bodies. AMA1-specific inhibitory antibodies were most
prevalent for W2mef and FVO; therefore, these were the
main focus of analyses. We found that high antibody
responders (defined as greater than the median) to FVO
and W2mef, determined by ELISA, had a higher preva-
lence of specific invasion inhibition of the P. falciparum
line engineered to express the relevant AMA1 allele
compared with low responders (P = 0.035 and 0.027,
respectively, Fisher’s exact test), and a similar trend was
observed for 3D7 (P = 0.16) but not Pf2006 (Fig. 6a).
(Prevalence of specific inhibition for HB3 and XIE was
Fig. 3 Representative examples of differential growth inhibition
of genetically engineered P. falciparum by human antibodies in
the PNG study . Comparisons are shown of lines tested in parallel
(3D7, FVO and HB3 (a) or W2mef, XIE and Pf2006 (b)) for inhibition by
serum samples from malaria-exposed PNG individuals. Columns
represent mean percentage growth inhibition (relative to control) of
duplicate wells from a single experiment. Error bars indicate + SEM
Fig. 2 Prevalence of antibodies to different AMA1 alleles measured
by ELISA. Error bars indicate + standard error. (n = 98 or 99 samples
tested for each allele)
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too low to be included in this analysis.) However,
many individuals with high levels of antibodies to an
AMA1 allele (measured by ELISA) lacked evidence of
AMA1-specific inhibitory antibodies. We also ex-
plored correlations between AMA1 allele-specific
inhibitory activity and ELISA reactivity. Inhibitory
antibodies were significantly more prevalent to the
FVO allele than the 3D7 allele, or to the W2Mef
allele compared to the XIE allele. However, there was
no significant correlation between the relative inhib-
ition of the FVO line versus the 3D7 expressing line
and IgG reactivity to recombinant FVO AMA1
proteins by ELISA, but there was a significant correl-
ation between the relative inhibition of W2Mef versus
XIE and antibodies to W2Mef-AMA1 by ELISA
(Spearman’s correlation ρ =0.55; P < 0.001). These
findings suggest that ELISA data are indicative of
functional activity to some extent, but they are not
strongly or consistently predictive of AMA1-specific
inhibitory activity and cannot be relied upon as a sur-
rogate of inhibitory activity.
Total growth-inhibitory activity by serum antibodies
against the lines expressing different AMA1 alleles was
significantly correlated with levels of antibodies to the
relevant AMA1 allele measured by ELISA (Spearman’s
correlation ρ = 0.44–0.68, P < 0.0001; n = 98 or 99)
(Additional file 1: Figure S5; Additional file 1: Table
S2), suggesting that ELISA antibodies might broadly
reflect the inhibitory potential of serum antibodies.
However, note that the total invasion-inhibitory activ-
ity of antibodies in these assays may be contributed
by antibodies to multiple antigens, not just AMA1, and
antibody invasion-inhibitory activity against P. falciparum
expressing a given AMA1 allele also correlated with IgG
reactivity to heterologous AMA1 alleles in most in-
stances, making it difficult to use standard ELISA as
a surrogate for AMA1-specific invasion-inhibitory
antibodies (Additional file 1: Table S2).
Fig. 4 Differential invasion inhibition of genetically engineered P. falciparum expressing different AMA1 alleles by antibodies in the PNG study. a
Prevalence of specific invasion inhibition (at least 10 % greater inhibition of one P. falciparum line compared with either of two other lines tested
at the same time) amongst PNG serum samples (n= 98 or 99). b Prevalence of PNG serum samples showing difference in invasion inhibition >10 %
between two P. falciparum lines (line A – line B) tested simultaneously (n= 98 or 99). Comparisons were made between lines tested together (3D7, FVO
and HB3, or W2mef, XIE and Pf2006). Error bars indicate + standard error (comparison of 3D7-FVO and HB3-FVO versus HB3-3D7, P= 0.003 and P = 0.0004,
respectively; XIE-W2Mef or Pf2006-W2Mef versus XIE-Pf2006, P < 0.0001). c, d Breadth of AMA1-specific growth-inhibitory activity in PNG population:
c overall (n= 98 or 99) and d amongst children (n= 48 or 49) versus adults (n= 50). Specific growth inhibition was considered present when there was
at least 10 % greater inhibition (absolute difference) of one genetically engineered P. falciparum line compared with either of two other lines tested at
the same time (3D7, FVO and HB3, or W2mef, XIE and Pf2006). There was a significant difference between children and adults in the proportion of
samples that differentially inhibited only one isolate (P< 0.05, Fisher’s exact test). Error bars indicate + standard error
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Invasion inhibition versus allele-specific AMA1 antibodies
measured by competition ELISA
We further investigated whether allele-specific anti-
bodies measured by competition ELISA might be used
as a surrogate of allele-specific, invasion-inhibitory anti-
bodies. We measured allele-specific antibodies by com-
petition ELISA amongst samples that showed at least
10 % greater inhibition of the W2-FVO AMA1 line than
the W2-3D7 AMA1 line (n = 24) and amongst samples
that did not show differential invasion inhibition (n = 64)
(Fig. 6b). Amongst sera with FVO-specific invasion in-
hibition (indicating presence of invasion-inhibitory anti-
bodies targeting FVO AMA1 but not 3D7 AMA1), there
was a higher overall level of allele-specific antibodies to
FVO AMA1 (that could not be competed by 3D7
AMA1 in competition ELISA) than allele-specific anti-
bodies to 3D7 AMA1 (P < 0.0001) (Fig. 6b). However,
many individuals with high levels of FVO AMA1-
Fig. 5 Overlap and allele specificity of AMA1-specific invasion-inhibitory antibodies. a Overlap in AMA1-specific invasion-inhibitory activity for the
three AMA1 alleles with the highest prevalence of inhibitory antibodies. Numbers of PNG individuals whose serum showed specific inhibition of
each line are shown. b Proportion of PNG samples (n = 98 or 99) showing specific inhibition of genetically engineered P. falciparum expressing
one allele of AMA1 that also inhibited growth of lines expressing other AMA1 alleles. Error bars indicate + SEM
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specific antibodies did not show significant FVO-specific
invasion-inhibitory activity (Fig. 6b), suggesting that
allele-specific antibodies measured by competition
ELISA are not strong correlates of allele-specific inhibi-
tory antibodies. Allele-specific, invasion-inhibitory anti-
bodies probably form a subset of total allele-specific
antibodies, suggesting that fine specificity, affinity or
other antibody properties are important for inhibitory
activity and that antibody levels measured by competi-
tion ELISA are not strongly predictive of functional
activity.
Prevalence of invasion-inhibitory AMA1 antibodies in
Kenyan adults
To investigate whether there are differences in the
acquisition of AMA1 inhibitory antibodies between
regions, we tested samples from adults in a malaria-
endemic region of Kenya for invasion inhibition and
antibodies to AMA1 by ELISA. The most prevalent in-
hibitory antibodies in Kenyan samples were to the FVO
(52 %) and XIE (50 %) AMA1 alleles (Fig. 7a). This dif-
fers from PNG, where the highest prevalence was to the
FVO and W2Mef AMA1 alleles, with a low prevalence
of inhibitory antibodies to XIE. Inhibitory antibodies to
Pf2006 were also more prevalent in Kenyan than in
PNG samples. Furthermore, the levels of inhibitory anti-
bodies were higher for FVO and XIE than the compari-
son lines, W2mef, HB3, Pf2006 or 3D7 (P < 0.0001;
Wilcoxon’s matched-pairs signed-rank sum test). Ana-
lysis of the cross-reactivity of inhibitory antibodies re-
vealed that most Kenyan serum samples were not
broadly cross-inhibitory, with few samples inhibiting
more than three different AMA1 lines (Fig. 7b), as seen
with the PNG samples. A higher proportion of sera
inhibited both FVO and XIE lines (79 % of FVO inhibi-
tors inhibited XIE and 83 % of XIE inhibitors inhibited
FVO) than was seen for the predominant inhibitory re-
sponses in PNG samples. Overall, results suggest there
was broader inhibitory activity amongst Kenyan samples
than PNG samples.
As was seen in PNG, the prevalence of AMA1 anti-
bodies measured by ELISA was high (92–98 % classified
as positive) and was similar for each of the six AMA1
alleles that were expressed by the genetically engineered
P. falciparum lines (Fig. 7c). Antibody responses were
strongly correlated between alleles (Spearman’s ρ = 0.86–
0.95, P < 0.0001), and the majority of serum samples
(92 %) were positive for each of the six AMA1 alleles
tested (Fig. 7d) (relative antibody levels did not clearly
reflect the pattern of inhibitory antibodies; Additional
file 1: Figure S6). When Kenyan sera samples that
showed an overlap in invasion-inhibitory activity were
compared with those that inhibited only a single genetic-
ally engineered P. falciparum line (e.g. FVO and XIE
versus FVO only), no difference was observed in anti-
body level by ELISA (P > 0.5184, Mann-Whitney U test)
or absolute invasion inhibition (P > 0.3823). Hence, simi-
lar to the results found for PNG sera, the overlap in
invasion-inhibitory activity of Kenyan sera is not related
to antibody magnitude measured by ELISA. Total
growth-inhibitory activity of lines expressing different
Fig. 6 AMA1-specific growth inhibition in low and high AMA1
antibody responders determined by ELISA. a Prevalence of specific
growth inhibition of genetically engineered P. falciparum expressing
different AMA1 alleles (>10 % inhibition of one line compared with
either of two other lines tested simultaneously), according to level
of antibody response to specific AMA1 alleles determined by ELISA
(high responses classified as greater than the median value) (n = 99).
Prevalence of specific inhibition for HB3 and XIE was too low to
be included in the analysis. Error bars indicate standard error. There
was a significant difference in the prevalence of FVO-specific and
W2mef-specific inhibitory antibodies between low and high
responders by ELISA (P < 0.05, Fisher’s exact test). b Allele-specific
antibodies to FVO and 3D7 AMA1 were measured by competition
ELISA in selected serum samples that showed FVO-specific growth
inhibition (growth of genetically engineered P. falciparum expressing
FVO at least 10 % lower than growth of genetically engineered
P. falciparum expressing 3D7 AMA1 (n = 24)), and amongst samples
with no differential growth inhibition (n = 64). Higher levels of FVO
allele-specific antibodies (FVO AMA1-specific antibodies that do not
cross-react with 3D7 AMA) than 3D7 allele-specific antibodies (3D7
AMA1-specific antibodies that do not cross-react with FVO AMA1)
were observed amongst samples with FVO-specific growth inhibition
(Mann-Whitney U test, P < 0.0001)
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AMA1 alleles by plasma antibodies was significantly cor-
related with levels of antibodies to the relevant AMA1
allele measured by ELISA (Additional file 1: Figure S7)
(Spearman’s ρ = 0.51–0.68, P < 0.0001, n = 54; Additional
file 1: Table S3). However, ELISA antibodies to heterol-
ogous AMA1 alleles were also significantly correlated
with inhibition of a given isolate expressing a specific
AMA1 allele (Spearman’s ρ = 0.44–0.69, P = 0.001 to P <
0.0001, n = 54; Additional file 1: Table S3). Therefore, it
was difficult to use standard ELISA to quantify or
estimate the presence of AMA1-specific inhibitory
antibodies.
We further explored the relationship between AMA1
allele-specific inhibitory antibodies and the reactivity of
antibodies to different AMA1 alleles measured by
ELISA. We first evaluated the correlation between
ELISA antibodies to FVO and 3D7 and the difference in
inhibitory activity between P. falciparum isolates ex-
pressing FVO and 3D7 alleles (since inhibitory anti-
bodies were highly prevalent to FVO, but not to 3D7).
We found that FVO-specific inhibitory antibodies (rela-
tive to 3D7) were not correlated with antibodies to FVO
by ELISA (Spearman’s ρ = –0.1101, P = 0.428). Further
analysis by ELISA also found no correlation between
antibodies to FVO and FVO-specific inhibitory anti-
bodies relative to HB3 (Spearman’s ρ = –0.1706, P =
0.2173), W2Mef (Spearman’s ρ = –0.2281, P = 0.0972),
XIE (Spearman’s ρ = –0.0845, P = 0.5435) or Pf2006
(Spearman’s ρ = –0.0633, P = 0.6488). Hence, while
AMA1 antibodies by ELISA are significantly correlated
with the total growth-inhibitory capacity of naturally
exposed Kenyan sera (Additional file 1: Table S3), they
do not appear to be predictive of AMA1-specific inhibi-
tory activity.
Discussion
The polymorphic nature of many malaria vaccine candi-
dates presents major challenges to achieving highly effi-
cacious vaccines. To date, there has been very little
knowledge on the prevalence and patterns of functional
immune responses to any polymorphic vaccine candi-
date in populations to guide vaccine design. Here we
studied AMA1 as an important vaccine candidate and as
a model for understanding functional immunity to poly-
morphic vaccine antigens in populations. We success-
fully developed a novel approach using P. falciparum
engineered to express different polymorphic variants of
AMA1 to quantify AMA1 as a target of naturally
Fig. 7 Prevalence of AMA1 allele-specific antibodies in Kenyan adults measured by invasion inhibition assays and ELISA. a Prevalence of AMA1
allele-specific invasion inhibition amongst adult Kenyan serum samples (n = 54). Error bars indicate standard error. b Prevalence of Kenyan serum
samples capable of inhibiting the growth of more than one transgenic parasite line. Error bars indicate standard error. c Prevalence of antibodies
to recombinant AMA1 by ELISA amongst Kenyan sera samples. Error bars indicate standard error. d Prevalence of Kenyan sera samples (n = 54)
that were antibody-positive by ELISA for multiple AMA1 alleles
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acquired inhibitory antibodies, thereby determining their
prevalence, strain specificity and functional importance
in immune sera. Our results reveal that AMA1 is a
major target of invasion-inhibitory human antibodies,
and these antibodies have a strong strain-specific com-
ponent to their activity. A highly significant finding is
that the prevalence of inhibitory antibodies varied sub-
stantially for different alleles, and this prevalence dif-
fered between geographic regions. This has major
implications for the selection of alleles for inclusion in a
multi-allele vaccine. Our studies showed that inhibitory
antibodies to the FVO allele were highly prevalent in
both geographic regions, and inhibitory antibodies were
also prevalent to W2Mef and XIE alleles/serotypes, iden-
tifying them as strong candidates for inclusion in future
AMA1 vaccines. These findings have major implications
for vaccine design, and it has not previously been pos-
sible to detect such serotypic differences in functional
immune responses by standard immunoassays. More-
over, for the first time, our approach enables measure-
ment of inhibitory antibodies at a population level,
which can be used to guide the selection of AMA1
alleles for inclusion in a future multi-allele vaccine. To
our knowledge, the allele/serotype-specific prevalence of
functional antibodies in populations has not been re-
ported for any malaria antigen or vaccine candidate to
date. These functional immunoassays will also be highly
valuable for evaluating immune responses and monitor-
ing vaccine escape in vaccine trials.
The selection of specific alleles, strains or serotypes
for inclusion in multi-allele or multi-strain vaccines typ-
ically needs to consider the predominant alleles or
strains circulating in target populations. This approach
has been used extensively with vaccines for other patho-
gens, including influenza, pneumococcus, meningococ-
cus and human papilloma virus. We propose that the
prevalence of allele-specific inhibitory antibodies in
target populations should be considered in vaccine de-
sign, and this study develops new tools to measure this.
Our studies establish an approach that could be used to
evaluate functional antibodies for other vaccine candi-
dates and quantify the importance of allele specificity
and population prevalence of allele-specific antibodies.
Given the enormous investment cost in taking vaccine
candidates through pre-clinical studies, GMP production
and into clinical trials, ensuring vaccine design addresses
issues of antigenic diversity and vaccine escape is
essential.
Data from multi-allele competition ELISAs amongst
human populations and studies of vaccine-induced anti-
bodies in rabbits suggest that the diversity in AMA1
may be covered by only a small number of different
AMA1 alleles [31, 32, 42, 43]. Tailoring vaccine design
to include the most prevalent alleles/serotypes, based on
assays measuring functional antibodies, would further
facilitate allele selection to maximize population cover-
age by AMA1 vaccines. In this study, the higher preva-
lence of inhibitory antibodies to FVO and W2mef alleles
in the PNG population and FVO and XIE in the Kenyan
population almost certainly reflects greater exposure to
these alleles in the respective study populations. Our
findings support the potential inclusion of these three
alleles (or closely related alleles) in a multi-allele AMA1
vaccine, particularly FVO, which was a prominent target
of inhibitory antibodies in both populations. However,
data are needed from other populations to further in-
form these selections and better define the extent of re-
gional differences. As there are more than 200 recorded
unique alleles of AMA1 [12–15, 30–32] and no evidence
of geographic clustering [33, 34], it is unlikely that iden-
tical forms of any one of the six AMA1 alleles tested in
this study are circulating at a high prevalence in either
population examined. Instead, it is likely that there are a
number of antigenically similar variants circulating, lead-
ing to the acquisition of functional antibodies. As such,
each of the AMA1 alleles included in this study appears
to represent a member of a distinct serotype or ser-
ogroup of AMA1 alleles that each share a collective set
of epitopes targeted by invasion-inhibitory antibodies.
Analysis of AMA1 sequences suggested that the ability
of AMA1 alleles to recruit T cell help is not a differenti-
ating factor in the ability of each AMA1 allele to elicit
functional antibody responses. Whilst the number of
human major histocompatibility complex (MHC) class II
binding peptides predicted to be present in AMA1 varies
greatly depending on the human leukocyte antigen
(HLA) allele examined, there is no significant difference
in the number of MHC class II binding peptides for a
given HLA allele across each of the six AMA1 alleles
examined in this study (data not shown; NetMHCII 2.2
server: http://www.cbs.dtu.dk/services/NetMHCII/). There
are also no data to suggest that the FVO, W2mef or XIE
alleles are inherently more susceptible to inhibitory
antibodies, and studies have shown comparable inhib-
ition of different alleles by vaccine-induced antibodies
[42, 43].
This is the first human population study to quantify
AMA1 as a target of naturally acquired invasion-
inhibitory antibodies and estimate the prevalence of
these inhibitory antibodies. Both children and adults in
PNG showed similar prevalence of AMA1-specific inva-
sion inhibition, and adults had a tendency for a higher
prevalence of inhibitory antibodies. In contrast to
AMA1, inhibitory antibodies to merozoite surface pro-
tein 1 (C-terminal region) were lower in both popula-
tions [39, 44].
Acquired human inhibitory AMA1 antibodies have
substantial allele-specific activity, rather than cross-
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reactive inhibition. The strain-specific nature of human
inhibitory antibodies we observed is consistent with the
strain-specific efficacy reported in a phase II AMA1 vac-
cine trial [2]. There was limited overlap in the inhibitory
activity of antibodies to different alleles. Whilst a high
prevalence of antibodies to all AMA1 alleles was found
by ELISA in PNG and Kenyan samples, invasion-
inhibitory antibodies to the FVO and W2mef AMA1 al-
leles in PNG and FVO and XIE AMA1 alleles in Kenya
were much more prevalent than invasion-inhibitory anti-
bodies to other AMA1 alleles. We explored the relation-
ship between antibodies to AMA1 measured by standard
ELISA, or allele-specific antibodies measured by compe-
tition ELISA, and AMA1-specific inhibitory antibodies.
We did find some significant associations between anti-
bodies measured by ELISA and AMA1-specific inhibi-
tory antibodies for some AMA1 alleles. However, these
associations were not consistent for all alleles, and over-
all, ELISA values were not highly predictive of allele-
specific inhibitory antibodies. This highlights the poten-
tial limitations of relying on standard immunoassays that
do not assess functional activity, which is influenced by
antibody fine specificity, avidity and other factors that
are not measured by ELISA. For example, a previous
study reported that the growth-inhibitory activity of nat-
urally acquired antibodies did not significantly correlate
with AMA1 antibodies measured by standard ELISA;
however, measuring antibodies to an inhibitory epitope
of AMA1 showed a better correlation with growth inhib-
ition [28]. Furthermore, AMA1 vaccine trials in malaria-
exposed populations have reported that the induction of
AMA1 antibodies measured by ELISA does not necessar-
ily predict the induction of functional inhibitory anti-
bodies [45, 46]. It has also been reported that some
acquired antibodies may interfere with the activity of
AMA1-specific invasion-inhibitory antibodies [29]. We
did find significant correlations between AMA1 antibody
reactivity and total growth-inhibitory activity of serum
antibodies. However, total growth-inhibitory activity is
mediated by antibodies to multiple antigens that are co-
acquired with increasing exposure to malaria [47], not just
by antibodies to AMA1. These observations and consider-
ations further emphasise the need for functional assays to
evaluate AMA1 in populations and clinical trials.
Our data are consistent with malaria-exposed individ-
uals acquiring a repertoire of allele-specific invasion-
inhibitory antibodies of multiple specificities, rather than
cross-inhibitory antibodies. Although ELISA data indi-
cate that humans acquire some cross-reactive anti-
bodies [12, 20, 21, 32], it might be that polymorphisms
have concentrated around functional epitopes in order to
facilitate evasion of protective antibodies [21]. The most
polymorphic residues in AMA1 occur adjacent to the
hydrophobic trough, which acts as a binding site for
RON2 [10, 48, 49]. Malaria exposure leads to the acquisi-
tion of antibodies to a highly polymorphic inhibitory epi-
tope around this region [28]. A longitudinal study showed
a strong association between polymorphisms in AMA1
and the development of symptomatic malaria and infec-
tion episodes [50]. Previous studies have shown that rabbit
antibodies raised against different AMA1 alleles inhibit in-
vasion of a panel of P. falciparum isolates to varying de-
grees, but may also show some cross-inhibitory activity
depending on the alleles being tested [31]. The present
data suggest that human antibodies are more strongly
allele-specific than antibodies from immunised animals;
this highlights the importance of studying human anti-
body responses to inform vaccine development and the
caveats in extrapolating results from vaccine studies per-
formed in small laboratory animals to human populations.
Although our ability to detect any samples with broadly
cross-inhibitory antibodies to AMA1 could potentially be
reduced using our approach, this appears unlikely to be a
major issue because our data, and those of others [32],
suggest that broadly cross-reactive antibodies to AMA1
do not occur, or are rare, amongst humans; furthermore,
they are not generated by standard immunisation ap-
proaches [31, 42]. It is not possible to delete the AMA1
gene and use AMA1-knockout parasites in functional as-
says, because AMA1 is essential in P. falciparum; there-
fore, allele replacement was the only approach possible to
quantify antibodies in functional assays. The predomin-
antly allele-specific nature of AMA1 inhibitory antibodies
demonstrated by these data indicates that a multi-allele
vaccine approach, or alternate strain-covering approach,
will be required for AMA1.
Conclusions
We successfully developed and applied a novel approach
to quantify functional immune responses to a poly-
morphic vaccine candidate in malaria-exposed popula-
tions using genetically engineered parasites. Our findings
indicate that AMA1 is a key target of invasion-inhibitory
antibodies that are largely allele-specific, and that the
prevalence of antibodies to different alleles varies sub-
stantially within and between populations. These findings
indicate that vaccine design, such as the selection of spe-
cific alleles for inclusion in a multi-allele vaccine, may need
to take account of the different population prevalence of
functional antibody serotypes. These findings are broadly
relevant to understanding immunity and vaccine design for
the many candidate malaria vaccine antigens that have
similar issues of antigen diversity, and suggest that further
studies are urgently needed to determine the distribution
of different serotypes or antigenic variants of leading
vaccine antigens, and the patterns of functional immunity
to these variants in different populations, to guide rationale
vaccine development and achieve maximal efficacy.
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